Cargando…

Assessing the Anti-Inflammatory Activity of the Anxiolytic Drug Buspirone Using CRISPR-Cas9 Gene Editing in LPS-Stimulated BV-2 Microglial Cells

Buspirone is an anxiolytic drug with robust serotonin receptor 1A (Htr1a) agonist activities. However, evidence has demonstrated that this drug also targets the dopamine D3 receptor (Drd3), where it acts as a potent antagonist. In vivo, Drd3 blockade is neuroprotective and reduces inflammation in mo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thomas Broome, Sarah, Fisher, Teagan, Faiz, Alen, Keay, Kevin A., Musumeci, Giuseppe, Al-Badri, Ghaith, Castorina, Alessandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8229595/ https://www.ncbi.nlm.nih.gov/pubmed/34070429 http://dx.doi.org/10.3390/cells10061312

Ejemplares similares

PACAP and VIP Modulate LPS-Induced Microglial Activation and Trigger Distinct Phenotypic Changes in Murine BV2 Microglial Cells
por: Karunia, Jocelyn, et al.
Publicado: (2021)

The Anxiolytic Drug Buspirone Prevents Rotenone-Induced Toxicity in a Mouse Model of Parkinson’s Disease
por: Thomas Broome, Sarah, et al.
Publicado: (2022)

PACAP and VIP Mitigate Rotenone-Induced Inflammation in BV-2 Microglial Cells
por: Broome, Sarah Thomas, et al.
Publicado: (2022)

Anxiolytic Effects of Buspirone and MTEP in the Porsolt Forced Swim Test
por: Lee, Kaziya M, et al.
Publicado: (2017)

Pro-Inflammatory and Pro-Apoptotic Effects of the Non-Protein Amino Acid L-Azetidine-2-Carboxylic Acid in BV2 Microglial Cells
por: Piper, Jordan Allan, et al.
Publicado: (2022)

Effects of ginsenoside Re on LPS-induced inflammatory mediators in BV2 microglial cells
por: Lee, Kang-Woo, et al.
Publicado: (2012)

Rapid GFAP and Iba1 expression changes in the female rat brain following spinal cord injury
por: Mandwie, Mawj, et al.
Publicado: (2021)

Ibrutinib suppresses LPS-induced neuroinflammatory responses in BV2 microglial cells and wild-type mice
por: Nam, Hye Yeon, et al.
Publicado: (2018)

Metformin Treatment Attenuates Brain Inflammation and Rescues PACAP/VIP Neuropeptide Alterations in Mice Fed a High-Fat Diet
por: Mandwie, Mawj, et al.
Publicado: (2021)

Anxiolytic-like Effects and Quantitative EEG Profile of Palmitone Induces Responses Like Buspirone Rather Than Diazepam as Clinical Drugs
por: Onofre-Campos, Daniela, et al.
Publicado: (2023)

Scoparone Inhibits LPS-Simulated Inflammatory Response by Suppressing IRF3 and ERK in BV-2 Microglial Cells
por: Cho, Duk-Yeon, et al.
Publicado: (2016)

Dopamine: an immune transmitter
por: Thomas Broome, Sarah, et al.
Publicado: (2020)

Interrogation of human microglial phagocytosis by CRISPR genome editing
por: Chang, Jason Cheng-Yu, et al.
Publicado: (2023)

LPS-Induced proNGF Synthesis and Release in the N9 and BV2 Microglial Cells: A New Pathway Underling Microglial Toxicity in Neuroinflammation
por: Duan, Li, et al.
Publicado: (2013)

Dopamine D3 Receptor Is Necessary for Ethanol Consumption: An Approach with Buspirone
por: Leggio, Gian Marco, et al.
Publicado: (2014)

CRISPR-Cas9 DNA Base-Editing and Prime-Editing
por: Kantor, Ariel, et al.
Publicado: (2020)

Salidroside Reduces Cell Mobility via NF-κB and MAPK Signaling in LPS-Induced BV2 Microglial Cells
por: Hu, Haixia, et al.
Publicado: (2014)

Hypoxia potentiates cytotoxicity of LPS-activated microglial BV2 cells in vitro by synergistic effects on cytokine and nitric oxide secretion
por: Jung, Susan, et al.
Publicado: (2015)

Idebenone Alleviates Neuroinflammation and Modulates Microglial Polarization in LPS-Stimulated BV2 Cells and MPTP-Induced Parkinson’s Disease Mice
por: Yan, Aijuan, et al.
Publicado: (2019)

Hispidin inhibits LPS-induced nitric oxide production in BV-2 microglial cells via ROS-dependent MAPK signaling
por: Jin, Mei-Hua, et al.
Publicado: (2021)

Commentary: RNA editing with CRISPR-Cas13
por: Matsoukas, Ianis G.
Publicado: (2018)

Genome Editing in Bacteria: CRISPR-Cas and Beyond
por: Arroyo-Olarte, Ruben D., et al.
Publicado: (2021)

CRISPR/Cas9 or prime editing? – It depends on…
por: Schenke, Dirk
Publicado: (2020)

Tackling dipeptidyl peptidase IV in neurological disorders
por: Al-Badri, Ghaith, et al.
Publicado: (2018)

Identification of Dysregulated microRNA Networks in Schwann Cell-Like Cultures Exposed to Immune Challenge: Potential Crosstalk with the Protective VIP/PACAP Neuropeptide System
por: Musumeci, Giuseppe, et al.
Publicado: (2018)

Microarray and Pathway Analysis Reveal Distinct Mechanisms Underlying Cannabinoid-Mediated Modulation of LPS-Induced Activation of BV-2 Microglial Cells
por: Juknat, Ana, et al.
Publicado: (2013)

Tryptanthrin Suppresses the Activation of the LPS-Treated BV2 Microglial Cell Line via Nrf2/HO-1 Antioxidant Signaling
por: Kwon, Young-Won, et al.
Publicado: (2017)

Involvement of NFƙB and MAPK signaling pathways in the preventive effects of Ganoderma lucidum on the inflammation of BV-2 microglial cells induced by LPS
por: Hilliard, Aaron, et al.
Publicado: (2020)

Modern Trends in Plant Genome Editing: An Inclusive Review of the CRISPR/Cas9 Toolbox
por: Razzaq, Ali, et al.
Publicado: (2019)

Inducible in vivo genome editing with CRISPR/Cas9
por: Dow, Lukas E, et al.
Publicado: (2015)

The Rise of CRISPR/Cas for Genome Editing in Stem Cells
por: Shui, Bing, et al.
Publicado: (2016)

Efficient Mitochondrial Genome Editing by CRISPR/Cas9
por: Jo, Areum, et al.
Publicado: (2015)

Multiplex genome editing of microorganisms using CRISPR-Cas
por: Adiego-Pérez, Belén, et al.
Publicado: (2019)

CRISPR/Cas9: Transcending the Reality of Genome Editing
por: Chira, Sergiu, et al.
Publicado: (2017)

Genome Editing in Cotton with the CRISPR/Cas9 System
por: Gao, Wei, et al.
Publicado: (2017)

Delivery Aspects of CRISPR/Cas for in Vivo Genome Editing
por: Wilbie, Danny, et al.
Publicado: (2019)

Applications of the CRISPR/Cas system beyond gene editing
por: Anton, Tobias, et al.
Publicado: (2018)

CRISPR/Cas9 Editing for Gaucher Disease Modelling
por: Pavan, Eleonora, et al.
Publicado: (2020)

Spatiotemporal control of CRISPR/Cas9 gene editing
por: Zhuo, Chenya, et al.
Publicado: (2021)

Nanoparticle Delivery of CRISPR/Cas9 for Genome Editing
por: Duan, Li, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3oal2gpb2q872p07hntpcaupbq